GENE SIGNATURE TO PREDICT HOMOLOGOUS RECOMBINATION (HR) DEFICIENT CANCER

Methods for identifying and treating cancers that are homologous recombination (HR)-repair defective. In some aspects, HR defective cancers are treated with a PARP inhibitor therapy. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided. L'invention concerne des procédés...

Full description

Saved in:
Bibliographic Details
Main Authors LIN, CHUN-JEN, MILLS, GORDON, PENG, GUANG, LIN, SHIAW-YIH
Format Patent
LanguageEnglish
French
Published 12.09.2014
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Methods for identifying and treating cancers that are homologous recombination (HR)-repair defective. In some aspects, HR defective cancers are treated with a PARP inhibitor therapy. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided. L'invention concerne des procédés d'identification et de traitement de cancers qui sont défectueux pour la réparation de recombinaison homologue (RH). Dans certains aspects, les cancers déficients en RH sont traités par une thérapie employant un inhibiteur de PARP. L'invention concerne également des procédés pour sensibiliser des cancers à une thérapie employant un inhibiteur de PARP.
Bibliography:Application Number: WO2014US20376